Muscle Glycogen Synthesis When Caffeine and Protein is Co-Ingested With Carbohydrates

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Maastricht University Medical Center.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT00975390
First received: September 10, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted
  Purpose

The aim of the present study is to investigate the effect of added protein+leucine or caffeine to 1.2 g/kg/h CHO on the rate of post-exercise muscle glycogen re-synthesis in healthy, recreational athletes.

The investigators hypothesize that both interventions (the addition of caffeine or protein+leucine) will lead to higher glycogen re-synthesis compared to the ingestion of CHO only, and that the co-ingestion of protein and leucine will result in the highest muscle glycogen synthesis rates.


Condition Intervention
Exercise Recovery
Dietary Supplement: Carbohydrate
Dietary Supplement: Carbohydrate and protein ingestion
Dietary Supplement: Carbohydrate and caffeine ingestion

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: The Effect of Caffeine or Protein Co-ingestion With Carbohydrate on Post-exercise Muscle Glycogen Synthesis Rate.

Resource links provided by NLM:


Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • Muscle glycogen synthesis rates [ Time Frame: 6 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Glycogen synthase activity, plasma glucose, insulin, free fatty acids and epinephrine responses [ Time Frame: 6 hours ] [ Designated as safety issue: No ]

Estimated Enrollment: 14
Study Start Date: February 2009
Estimated Study Completion Date: November 2009
Estimated Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Carbohydrate ingestion
Dietary Supplement: Carbohydrate
1.2 g/kg/h
Experimental: 2
Carbohydrate and protein ingestion
Dietary Supplement: Carbohydrate and protein ingestion
1.2 g/kg/h carbohydrate plus 0.4 g/kg/h protein
Experimental: 3
Carbohydrate and caffeine ingestion
Dietary Supplement: Carbohydrate and caffeine ingestion
1.2 g/kg/h carbohydrate and 1.67 g/kg/h caffeine

  Eligibility

Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • male cyclists
  • healthy
  • BMI < 25

Exclusion Criteria:

  • female
  • use of medication
  • non cycling
  • BMI > 25
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00975390

Locations
Netherlands
Maastricht University
Maastricht, Netherlands
Sponsors and Collaborators
Maastricht University Medical Center
  More Information

No publications provided

Responsible Party: Luc van Loon, Maastricht University
ClinicalTrials.gov Identifier: NCT00975390     History of Changes
Other Study ID Numbers: 08-3-066
Study First Received: September 10, 2009
Last Updated: September 10, 2009
Health Authority: Netherlands: Medical Ethics Review Committee (METC)

Keywords provided by Maastricht University Medical Center:
Glycogen
Carbohydrate
Protein
Caffeine
Post exercise muscle glycogen synthesis
Sports nutrition

Additional relevant MeSH terms:
Caffeine
Central Nervous System Stimulants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents

ClinicalTrials.gov processed this record on September 30, 2014